These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 932225)

  • 21. A fully automated immuno-turbidimetric determination of fibrin(ogen) degradation products.
    Hoak DR; Mammen EF; Banerjee SK; Kaldor G
    Thromb Res; 1986 Oct; 44(1):1-10. PubMed ID: 3538493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of D dimer in patients with elevated fibrinogen degradation products in serum: further study in chronic myelogenous leukemia.
    Saito M; Asakura H; Jokaji H; Uotanzi C; Kumabashiri I; Yoshida T; Hashizume K; Matsuda T
    Acta Haematol; 1990; 84(3):149-55. PubMed ID: 2123066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
    McCarron BI; Marder VJ; Francis CW
    Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in fibrinogen and fibrin-related antigen in human serum due to in vitro lysis of fibrin by thrombin.
    Merskey C; Johnson AJ; Lalezari P
    J Clin Invest; 1972 Apr; 51(4):903-11. PubMed ID: 5014617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
    Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
    Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of fibrin formation in exercise-induced activation of coagulation.
    Vogt A; Hofmann V; Straub PW
    Am J Physiol; 1979 Apr; 236(4):H577-9. PubMed ID: 434223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticlotting properties of fragments D from human fibrinogen and fibrin.
    Haverkate F; Timan G; Nieuwenhuizen W
    Eur J Clin Invest; 1979 Aug; 9(4):253-5. PubMed ID: 118016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development of radioimmunoassays for fibrinogen degradation products: fragments D and E.
    Gordon YB; Martin MJ; Landon J; Chard T
    Br J Haematol; 1975 Jan; 29(1):109-19. PubMed ID: 1201195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of anticoagulant and storage conditions on bovine nonesterified fatty acid and beta-hydroxybutyrate concentrations in blood.
    Stokol T; Nydam DV
    J Dairy Sci; 2005 Sep; 88(9):3139-44. PubMed ID: 16107403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiogenic activity of fibrin degradation products is located in fibrin fragment E.
    Thompson WD; Smith EB; Stirk CM; Marshall FI; Stout AJ; Kocchar A
    J Pathol; 1992 Sep; 168(1):47-53. PubMed ID: 1280677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
    Eisses MJ; Velan T; Aldea GS; Chandler WL
    Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of enzyme-linked immunosorbent assay to measure thrombin-antithrombin III complexes in horses with colic.
    Topper MJ; Prasse KW
    Am J Vet Res; 1996 Apr; 57(4):456-62. PubMed ID: 8712506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum.
    Böttger R; Hoffmann R; Knappe D
    PLoS One; 2017; 12(6):e0178943. PubMed ID: 28575099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of different storage temperatures, sample collection procedures and immunoassay methods on osteocalcin measurement.
    Noonan K; Kalu ME; Holownia P; Burrin JM
    Eur J Clin Chem Clin Biochem; 1996 Oct; 34(10):841-4. PubMed ID: 8933109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature.
    Zürcher M; Sulzer I; Barizzi G; Lämmle B; Alberio L
    Thromb Haemost; 2008 Feb; 99(2):416-26. PubMed ID: 18278194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A diazophenylthio-ether-IgG probe for analysing fibrin- and fibrinogen-related antigens.
    Kruskal JB; Maeder DL; Purves LR; Franks JJ; Kirsch RE
    S Afr Med J; 1987 Feb; 71(4):211-7. PubMed ID: 3824087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agreement of D-dimer results measured by a rapid ELISA (VIDAS) before and after storage during 24h or transportation of the original whole blood samples.
    Caliezi C; Reber G; Lämmle B; de Moerloose P; Wuillemin WA
    Thromb Haemost; 2000 Jan; 83(1):177-8. PubMed ID: 10669177
    [No Abstract]   [Full Text] [Related]  

  • 38. Measurement of fibrinopeptide A in human blood.
    Nossel HL; Yudelman I; Canfield RE; Butler VP; Spanondis K; Wilner GD; Qureshi GD
    J Clin Invest; 1974 Jul; 54(1):43-53. PubMed ID: 4600045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of coagulation test results for blood samples obtained by means of direct venipuncture and through a jugular vein catheter in clinically normal dogs.
    Millis DL; Hawkins E; Jager M; Boyle CR
    J Am Vet Med Assoc; 1995 Nov; 207(10):1311-4. PubMed ID: 7591925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unreliability of current serum fibrin degradation product (FDP) assays.
    Gaffney PJ; Perry MJ
    Thromb Haemost; 1985 Jun; 53(3):301-2. PubMed ID: 3901388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.